CPRX beat EPS expectations by 29.76%
May 08, 2025, 10:34 AM
0.00%
What does CPRX do
Catalyst Pharmaceuticals, based in Coral Gables, Florida, develops and commercializes novel medicines for rare diseases, including FIRDAPSE for Lambert-Eaton Myasthenic Syndrome and AGAMREE for Duchenne Muscular Dystrophy. The company, which went public in 2006, employs 167 people.
Catalyst Pharmaceuticals (CPRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Catalyst Pharmaceuticals's actual EPS was $0.45, beating the estimate of $0.35 per share, resulting in a 29.76% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.